534个药品通过2025年国家医保药品目录形式审查

Group 1 - The National Medical Insurance Administration (NMIA) announced the preliminary results of the 2025 National Medical Insurance Drug List review, with 534 drugs passing the formal review, indicating an increase in the number of drug applications compared to 2024 [1] - The adjustment process for the medical insurance drug list includes several stages: enterprise application, formal review, expert evaluation, negotiation and bidding, and price consultation [1] - A new category for commercial insurance innovative drugs has been added this year, with 141 generic drug names submitted for review, of which 121 passed the formal review [1] Group 2 - Some drugs applied for both the basic medical insurance list and the commercial insurance innovative drug list, leading to potential discrepancies in the review results due to differing application criteria [1] - Expensive drugs that exceed the basic medical insurance coverage may pass the preliminary formal review, but their final inclusion in the basic medical insurance list depends on strict evaluation procedures, including successful negotiations for exclusive drugs and competitive bidding for non-exclusive drugs [1] - The public consultation period for the announced results will end on August 18, during which the NMIA will review feedback and finalize the list of drugs that passed the formal review [2]